AbstractPurpose:WeconductedaphaseIIstudyofcombinationchemotherapywithirinotecan(CPT-11)andnedaplatin(NDP),(INPregimen),todeterminetheeffectsandtoxicitiesinpatientswithextensivestagesmallcelllungcancer(SCLC).Methods:FromMarch2005toDecember2010,60patientswithhistologicallyorcytologicallyconfirmedextensiveSCLCwereenrolledintothisstudy.AllreceivedtreatmentCPT-11atadoseof60mg/m2ondays1and8,andNDP20mg/m2ondays1-5,every3-4weeksasacycle.Patientsweretreateduntiltumorprogressionorunacceptabletoxicity.Results:Maintoxicitiesincluded:myelosuppression,nauseaorvomiting,diarrhea,elevationofalanineaminotransferase,andbilirubin.Notreatmentrelateddeathoccurredinthisstudy.Thirteenpatientshadcompleteresponse,forty-twohadpartialresponse,threeremainedstable,andtwohadprogressivedisease.Medianprogression-freesurvivalwas13months(95%confidenceinterval:9-17)andmedianoverallsurvivalwas22months(95%confidenceinterval:19-25).Conclusion:INPisaneffectiveandwelltoleratedregimenfortreatmentofextensivestagedSCLC.
